Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.
Nicholas Vogelzang, MD, FASCO, FACP: When you have used, in this case apalutamide, you have used the best androgen receptor inhibition. The role of second-line androgen receptor therapy with abiraterone or enzalutamide is quite uncertain, and there may not be much left to do. The CARD study, for example, looked at patients who had previous abiraterone or enzalutamide, and randomized them to the alternative androgen receptor inhibitor or to cabazitaxel. Cabazitaxel was superior in those patients. I do not think there is a big role for a second-line androgen receptor inhibitor for these patients. In the majority of patients after failure of abiraterone, enzalutamide, or apalutamide, you are left with having to go to chemotherapy, or radium, sipuleucel-T, or one of those sorts of drugs. For a long time, we were quite enamored with the use of a second androgen receptor inhibitor. The CARD trial has deflated our optimism about that sequence. I would still do it, and most doctors, particularly prostate cancer doctors, would do it, but there is not a high level of benefit for most patients.
I mentioned my patient with Bloom syndrome who has a PSA [prostate-specific antigen] doubling time of 1 month, and I explained to him that this was not a good thing. Yesterday I said to him, “We better be prepared for some bad outcomes.” He feels perfectly well. He has nothing but a fast doubling time and minimal disease. But the Johns Hopkins [University] study many years ago from Mario Eisenberger, [MD,] and that team said that a PSA doubling time of under 3 months is an ominous finding, and you have to be prepared to change therapies if you start seeing a rapid PSA doubling time. As long as you are prepared and as long as you explain the significance of it to the patient, you can be ready for it. We have options, like I said, you have PARP inhibitors, sipuleucel-T, radium, and several types of chemotherapy. You have platinum agents, so those are all good drugs. We simply have to be prepared to deploy them at the right time.
Transcript edited for clarity.
Case: A 76-Year-Old Male With Recurrent Castrate-Sensitive Prostate Cancer
History
Currently
Clinical workup
Treatment and Follow-Up
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More